Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Vaccitech plc Create: Alert

All | News | Filings
Date FiledTypeDescription
10/05/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
Docs: "Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments OXFORD, United Kingdom, August 10, 2023 -- Vaccitech plc , a clinical-stage biopharmaceutical company engaged in the discovery and development of novel T cell immunotherapeutics designed to harness the power of the immune system to treat chronic infectious diseases, cancer and autoimmunity, today announced its financial results for the second quarter of 2023 and provided an overview of the Company’ s progress. “In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL,” said Bill Enright, Vaccitech’ s Chief Executive Officer. “Looking ahead, we rem..."
07/26/2023 8-K Quarterly results
05/12/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/12/2023 8-K Investor presentation, Quarterly results
Docs: "Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments OXFORD, United Kingdom, May 12, 2023 -- Vaccitech plc , a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for the first quarter of 2023 and an overview of the Company’ s progress. “2023 has kicked off strongly for Vaccitech. In the first quarter, we strengthened our leadership team with the addition of Dr. Nadège Pelletier as our new Chief Scientific Officer, we generated positive final proof of concept data from one of our hepatitis B trials, and very promising interim data from our human papillomavirus...",
"Investor Presentation dated May 2023"
05/11/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
04/19/2023 ARS Form ARS - Annual Report to Security Holders:
03/29/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/24/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/24/2023 10-K Annual Report for the period ended December 31, 2022
03/24/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments OXFORD, United Kingdom, March 24, 2023 -- Vaccitech plc , a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, autoimmunity and cancer, today announced its financial results for year end 2022 and an overview of the Company’ s progress. “2022 represented an extremely active year at Vaccitech in which the company continued to advance its exciting pipeline and strengthen the infrastructure necessary to support this and future growth. We announced the completion of enrollment of three clinical trials, and initiated dosing in three new trials. This, combined with the announcemen..."
02/10/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
02/10/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
02/10/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
02/10/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
02/10/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
02/10/2023 5 Form 5 - Annual statement of changes in beneficial ownership of securities:
01/20/2023 SC 13G/A M&G INVESTMENT MANAGEMENT LTD reports a 13.9% stake in Vaccitech Plc
10/07/2022 SC 13G M&G INVESTMENT MANAGEMENT LTD reports a 14% stake in Vaccitech Plc
09/30/2022 8-K/A Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/20/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Vaccitech Promotes Gemma Brown as Chief Financial Officer OXFORD, United Kingdom, Sept. 20, 2022 -- Vaccitech plc , a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced the promotion of Gemma Brown as Chief Financial Officer . Gemma Brown succeeds Georgy Egorov. “Gemma has been highly engaged with all financial activities at Vaccitech including working with our auditors, corporate budgeting, SEC financial filings and other activities so we anticipate a seamless transition,” said Bill Enright, Chief Executive Officer of Vaccitech. “I want to personally thank Georgy for his contributions to Vaccitech particularly his efforts that led to our successful IPO in 2021. We wish him the best in his future endea..."
08/18/2022 EFFECT Form EFFECT - Notice of Effectiveness:
08/10/2022 S-3/A Form S-3/A - Registration statement under Securities Act of 1933: [Amend]
08/09/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
07/08/2022 EFFECT Form EFFECT - Notice of Effectiveness:
06/28/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Vaccitech’s VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1"
06/22/2022 S-3 Form S-3 - Registration statement under Securities Act of 1933:
06/16/2022 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/24/2022 8-K/A Quarterly results
05/13/2022 DEFR14A Form DEFR14A - Revised definitive proxy soliciting materials:
05/13/2022 8-K Quarterly results
05/11/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/11/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy